Vericel Management

Management criteria checks 3/4

Vericel's CEO is Nick Colangelo, appointed in Mar 2013, has a tenure of 11.08 years. total yearly compensation is $7.06M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €8.39M. The average tenure of the management team and the board of directors is 3.8 years and 10.9 years respectively.

Key information

Nick Colangelo

Chief executive officer

US$7.1m

Total compensation

CEO salary percentage	11.2%
CEO tenure	11.1yrs
CEO ownership	0.4%
Management average tenure	3.8yrs
Board average tenure	10.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nick Colangelo's remuneration changed compared to Vericel's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$7m	US$790k	-US$3m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$9m	US$760k	-US$17m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$16m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$13m	US$730k	-US$7m
Sep 30 2021	n/a	n/a	US$214k
Jun 30 2021	n/a	n/a	US$9m
Mar 31 2021	n/a	n/a	US$4m
Dec 31 2020	US$4m	US$675k	US$3m
Sep 30 2020	n/a	n/a	US$145k
Jun 30 2020	n/a	n/a	-US$3k
Mar 31 2020	n/a	n/a	-US$12m
Dec 31 2019	US$5m	US$634k	-US$10m
Sep 30 2019	n/a	n/a	-US$14m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$3m	US$592k	-US$8m
Sep 30 2018	n/a	n/a	-US$13m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$1m	US$556k	-US$17m

Compensation vs Market: Nick's total compensation ($USD7.06M) is above average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.

CEO

Nick Colangelo (59 yo)

11.1yrs

Tenure

US$7,056,422

Compensation

Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation since March 1, 2013 and served as its Treasurer since May 7, 2014. He has been...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dominick Colangelo	CEO, President & Director	11.1yrs	US$7.06m	0.40% $ 8.4m
Joseph Mara	CFO & Treasurer	3.3yrs	US$2.15m	0.040% $ 832.1k
Michael Halpin	Chief Operating Officer	4.8yrs	US$2.38m	0.0020% $ 40.9k
Sean Flynn	Chief Legal Officer	4.4yrs	US$1.56m	0.00098% $ 20.3k
Jonathan Hopper	Chief Medical Officer	5.7yrs	US$1.58m	0.12% $ 2.5m
Jonathan Siegal	Principal Accounting Officer	2.2yrs	no data	0.0029% $ 60.1k
Eric Burns	Vice President of Finance & Investor Relations	no data	no data	no data
Patrick Fowler	Senior Vice President of Corporate Development & Strategy	2.6yrs	no data	no data
Patrick Helfrich	Vice President of Marketing & Commercial Strategy	less than a year	no data	no data
Mike Gilligan	Senior Vice President of Sales	less than a year	no data	no data
Heidi Hassen	Senior Vice President of Human Resources	no data	no data	no data
Roland DeAngelis	Chief Commercial Officer	4.6yrs	no data	no data

3.8yrs

Average Tenure

59yo

Average Age

Experienced Management: ATQP's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dominick Colangelo	CEO, President & Director	11.1yrs	US$7.06m	0.40% $ 8.4m
Kevin McLaughlin	Independent Director	9.3yrs	US$327.14k	0.018% $ 373.8k
Paul Wotton	Independent Director	9.3yrs	US$265.05k	0.056% $ 1.2m
Robert Zerbe	Independent Chairman & Lead Director	18.3yrs	US$354.64k	0.048% $ 1.0m
Alan Rubino	Independent Director	18.6yrs	US$285.05k	0.043% $ 884.6k
Steven Gilman	Independent Director	9.3yrs	US$314.64k	0.016% $ 335.0k
Joyce Frey-Vasconcells	Member of Scientific Advisory Board	no data	no data	no data
Mahendra Rao	Member of Scientific Advisory Board	14yrs	no data	no data
Karen Hirschi	Member of Scientific Advisory Board	14yrs	no data	no data
Heidi Hagen	Independent Director	10.7yrs	US$324.64k	0.032% $ 663.5k
Lisa Wright	Independent Director	2.8yrs	US$312.14k	0.012% $ 249.9k

10.9yrs

Average Tenure

63yo

Average Age

Experienced Board: ATQP's board of directors are seasoned and experienced ( 10.9 years average tenure).

Vericel Management

Management criteria checks 3/4

Key information

Recent management updates

Vericel Corporation, Annual General Meeting, May 01, 2024

Senior VP recently sold €336k worth of stock

Vericel Corporation Announces Appointment of Jonathan Siegal as Principal Accounting Officer

Insufficient new directors

Independent Director recently sold €208k worth of stock

Vericel Corporation, Annual General Meeting, Apr 28, 2021

Recent updates

Vericel Corporation to Report Q1, 2024 Results on May 08, 2024

Vericel Corporation, Annual General Meeting, May 01, 2024

Senior VP recently sold €336k worth of stock

Full year 2023 earnings released: US$0.067 loss per share (vs US$0.35 loss in FY 2022)

Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024

Vericel Corporation to Report Q4, 2023 Results on Feb 29, 2024

Vericel Corporation Provides Earnings Guidance for the Year 2024

Vericel Corporation Provides Earnings Guidance for the Fourth Quarter and Full-Year 2023

Third quarter 2023 earnings released: US$0.077 loss per share (vs US$0.14 loss in 3Q 2022)

Vericel Corporation Provides Total Net Revenue Guidance for 2023

Vericel Corporation to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Vericel Corporation Announces U.S. Commercial Availability of NexoBrid (Anacaulase-Bbb) for the Treatment of Severe Thermal Burns in Adults

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2022)

Vericel Corporation Revises Earnings Guidance for the Year 2023

Vericel Corporation to Report Q2, 2023 Results on Aug 02, 2023

Vericel Corporation Raises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 1Q 2022)

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.16 loss in FY 2021)

Vericel Corporation to Report Q4, 2022 Results on Feb 23, 2023

Vericel Corporation Announces Accelerated Launch Timeline for MACI Arthroscopic Program

Vericel Corporation Provides Revenue Guidance for the Full-Year 2022

Vericel Announces Fda Approval of Nexobrid for the Treatment of Severe Thermal Burns in Adults

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.11 loss in 3Q 2021)

Vericel Corporation Provides Earnings Guidance for the Full-Year 2022

Vericel Corporation to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.082 loss in 2Q 2021)

Vericel Corporation Announces Revenue Guidance for the Full Year of 2022

Vericel Corporation Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America of Patients with Large Posterior Trunk Burns Treated with Epicel

Vericel Corporation to Report Q2, 2022 Results on Aug 03, 2022

First quarter 2022 earnings released: US$0.15 loss per share (vs US$0.072 loss in 1Q 2021)

Vericel Corporation Reaffirms Earnings Guidance for the Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vericel Corporation Announces Appointment of Jonathan Siegal as Principal Accounting Officer

Vericel Corporation to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.08 profit in 3Q 2020)

Vericel Corporation Raises Revenue Guidance for the Year 2021

Second quarter 2021 earnings released: US$0.082 loss per share (vs US$0.18 loss in 2Q 2020)

Insufficient new directors

VP, Principal Accounting Officer & Controller Sandra Pennell has left the company

Vericel Corporation(NasdaqCM:VCEL) dropped from Russell Microcap Growth Index

Vericel Corporation Provides Revenue Guidance for the Year 2021

Independent Director recently sold €208k worth of stock

First quarter 2021 earnings released: US$0.072 loss per share (vs US$0.10 loss in 1Q 2020)

Vericel Corporation Provides Earnings Guidance for the Full Year 2021

Vericel Corporation, Annual General Meeting, Apr 28, 2021

Full year 2020 earnings released: EPS US$0.063 (vs US$0.22 loss in FY 2019)

Revenue beats expectations

New 90-day high: €36.76

Vericel Corporation Announces the Appointment of Joseph A. Mara as Chief Financial Officer

New 90-day high: €25.44

New 90-day high: €22.13

New 90-day high: €18.88

Third quarter 2020 earnings released: EPS US$0.08

Revenue beats expectations

New 90-day high: €16.29

Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

New 90-day high - €14.83

First half earnings released

Vericel Corporation to Report Q2, 2020 Results on Aug 05, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure